MERRIMACK PHARMACEUTICALS INC
DelistedCIK 1274792fmd_16RPR3QBM3PHPV6JX2EQQS5QP3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Mar 31, 2024, 54 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 92 | 89 | 144 | – | – | – | – | – | – | – |
| Cost of revenue | 0 | 0 | 7 | – | – | – | – | – | – | – |
| Gross profit | 92 | 89 | 137 | – | – | – | – | – | – | – |
| Research and development | 103 | 121 | 110 | 67 | 50 | 11 | – | – | – | – |
| Selling, general and administrative | 31 | 58 | 81 | – | – | – | – | – | – | – |
| Total operating expenses | – | – | – | 96 | 66 | 22 | 3 | 2 | 2 | 2 |
| Operating income | (30) | (145) | (147) | (96) | (66) | (22) | (3) | (2) | (2) | (2) |
| Interest expense | 18 | 19 | 22 | 35 | 1 | 2 | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
| Other non-operating income (expense) | 1 | 1 | (0) | (23) | (3) | (0) | (0) | 0 | 0 | 1 |
| Income before taxes | (47) | (163) | (170) | (118) | (68) | (23) | (3) | (2) | (2) | (1) |
| Income tax expense | – | (11) | (13) | (42) | (8) | (1) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (47) | (152) | (156) | (76) | (61) | (21) | (3) | (2) | (2) | (1) |
| Net income | (83) | (148) | (152) | 472 | (41) | (17) | (3) | (2) | (2) | (1) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |